Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year Low – Here’s Why

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) hit a new 52-week low on Tuesday. The stock traded as low as $29.00 and last traded at $29.00, with a volume of 24,865 shares changing hands. The stock had previously closed at $41.92.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SUPN shares. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Reduce” and an average target price of $62.33.

Supernus Pharmaceuticals Stock Performance

The business’s fifty day moving average price is $42.42 and its 200-day moving average price is $47.27. The stock has a market cap of $1.75 billion, a PE ratio of -39.01, a P/E/G ratio of 1.21 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million for the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.80) earnings per share. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Dividend Announcement

The business also recently announced a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be given a $8.13 dividend.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. Public Employees Retirement System of Ohio bought a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $25,000. Rockefeller Capital Management L.P. boosted its stake in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares during the last quarter. Heritage Family Offices LLP purchased a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth $39,000. Global Retirement Partners LLC purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $64,000. Finally, Versant Capital Management Inc grew its position in shares of Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.